Seattle Genetics, Inc. (NASDAQ:SGEN)

CAPS Rating: 4 out of 5

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

Results 1 - 20 of 77 : 1 2 3 4 Next »

Recs

0
Member Avatar 1badbeerad (32.99) Submitted: 12/16/2014 6:16:55 PM : Outperform Start Price: $31.78 SGEN Score: -4.16

Just a question of time before this takes off like a bottle rocket. The shorts can't hold it down forever.

Recs

0
Member Avatar Tophinater (38.78) Submitted: 11/11/2014 1:55:45 PM : Outperform Start Price: $37.03 SGEN Score: -15.84

Its a biotech.

Recs

0
Member Avatar TSIF (99.96) Submitted: 10/14/2014 7:11:59 PM : Outperform Start Price: $31.17 SGEN Score: -7.08

Seattle Genetics, Inc has been a spec play for me a few times. The depressed share price is a function of the current market and mixed opinion on their latest Phase III results which they are trying to use to expand approval of Hodgkin lymphoma drug Adcetris. high risk" Hodgkin lymphoma patients immediately after a stem-cell transplant led to a 43% reduction in the risk of disease progression compared to placebo.

The problems seems to be that it didn't extend life against a placebo, but Seattle claims crossing over in the study groups.

There is not a large population that fits this model, and there is a question of whether Doctors will use it immediately after the stem cell replacement or only on renewed progression.

Seattle Genetics has a BROAD portfolio and world class partners. Cash should hold up awhile and the debate on even the worse outcome for Adcetris additional use is minor compared to the pipeline.

Biopharms are risky. I like Seattle long term and will watch short term gyrations for a change of thesis, but $32 seems to be fair price at this level.

Recs

0
Member Avatar SnowBawl (< 20) Submitted: 7/15/2014 12:36:51 PM : Outperform Start Price: $35.27 SGEN Score: -15.03

Sterman, insider buying, 1 of 4.

Recs

0
Member Avatar tiobueno (99.55) Submitted: 6/5/2014 9:23:04 AM : Outperform Start Price: $36.90 SGEN Score: -21.05

Insider(1)

Recs

1
Member Avatar trackjakeambrose (55.54) Submitted: 12/17/2013 11:20:49 AM : Outperform Start Price: $39.11 SGEN Score: -35.10

1

Recs

1
Member Avatar biostrategy (< 20) Submitted: 11/6/2013 4:38:30 AM : Outperform Start Price: $37.98 SGEN Score: -33.77

Seattle Genetics share price has been trending lower lately due to adverse side effects experienced by some patients undergoing clinical trials with the company’s lead product Adcetris. Since long term prospects look bright for this company, this could be a nice chance for value investors to enter the stock.

Recs

1
Member Avatar bigstylianos (73.76) Submitted: 10/10/2013 10:12:52 AM : Outperform Start Price: $40.30 SGEN Score: -44.89

Cancer treatment endorsed by big pharma

Recs

1
Member Avatar 1russianguy (79.88) Submitted: 10/9/2013 2:17:22 PM : Outperform Start Price: $39.85 SGEN Score: -45.37

As per Cramer's 08/28/2013: Medivation (MDVN_), Seattle Genetics (SGEN_) and BioMarin (BMRN_): A wave of biotech acquisitions could be coming, said Cramer, and these three companies are prime takeover targets.

Recs

2
Member Avatar prbaker76 (< 20) Submitted: 10/6/2013 4:07:11 PM : Outperform Start Price: $44.82 SGEN Score: -53.10

Successful biotech with flagship drug adcentris, being used now internationally and more broadly in the US. Also great pipeline for development of other drugs.

Recs

0
Member Avatar 1picks (87.69) Submitted: 9/24/2013 10:08:03 AM : Outperform Start Price: $43.81 SGEN Score: -49.95

http://www.insidermonkey.com/blog/seattle-genetics-inc-sgen-celldex-therapeutics-inc-cldx-this-company-has-potential-to-grow-215929/

Cancer is the target of a number of different biotech companies. Out of this lot, I consider Seattle Genetics, Inc. (NASDAQ:SGEN) to be one of the star performers. Why is that? Because the company has one of the best antibody therapeutic study facilities and is one of the most successful in the industry. Its main focus is cancer, which is one of the leading causes of deaths in the U.S. Over the last one year, the company has gone up by over 75%, trading currently at an all-time high of around $40.52. The company has strong pipeline which target various types of cancers.

Seattle Genetics, Inc. (NASDAQ:SGEN) is quite well established, because it currently has an FDA approved drug in the market. Adcetris, the flag ship product of the company, got its FDA approval in August 2011 for the treatment of relapsed Hodgkin's Lymphoma and Large Cell Lymphoma patients. Hodgkin's Lymphoma is a type of cancer which attacks the lymph tissue including liver, bone marrow, lymph nodes, and others. The company had a good run in 2012 due to the revenue generated by Adcetris. The company made some $210 million last year, compared to just $95 million in 2011.

Seattle Genetics, Inc. (NASDAQ:SGEN) also has a number of other drugs which would be out in the market after two to three years. The company has more than 15 antibody conjugates in clinical development; some wholly owned by it, and others in collaboration with other companies. Analysts are expecting that in the long term, once one of these drugs reaches its potential, Seattle can generate around $3.5 billion in revenue and royalties payments from its collaborations.

Cancer is the target of a number of different biotech companies. Out of this lot, I consider Seattle Genetics, Inc. (NASDAQ:SGEN) to be one of the star performers. Why is that? Because the company has one of the best antibody therapeutic study facilities and is one of the most successful in the industry. Its main focus is cancer, which is one of the leading causes of deaths in the U.S. Over the last one year, the company has gone up by over 75%, trading currently at an all-time high of around $40.52. The company has strong pipeline which target various types of cancers.
Adcetris did the trick…
Seattle Genetics, Inc.Seattle Genetics, Inc. (NASDAQ:SGEN) is quite well established, because it currently has an FDA approved drug in the market. Adcetris, the flag ship product of the company, got its FDA approval in August 2011 for the treatment of relapsed Hodgkin's Lymphoma and Large Cell Lymphoma patients. Hodgkin's Lymphoma is a type of cancer which attacks the lymph tissue including liver, bone marrow, lymph nodes, and others. The company had a good run in 2012 due to the revenue generated by Adcetris. The company made some $210 million last year, compared to just $95 million in 2011.
Seattle Genetics, Inc. (NASDAQ:SGEN) also has a number of other drugs which would be out in the market after two to three years. The company has more than 15 antibody conjugates in clinical development; some wholly owned by it, and others in collaborationwith other companies. Analysts are expecting that in the long term, once one of these drugs reaches its potential, Seattle can generate around $3.5 billion in revenue and royalties payments from its collaborations.

Bayer collaboration
At the end of June, Seattle announced that it’s working on a new antibody drug conjugate in collaboration with Bayer Healthcare. This deal allows Bayer the right to market and sell Seattle Genetics, Inc. (NASDAQ:SGEN)’ cytotoxic agents, i.e. auristatin-based antibody technology with oncology targets worldwide. For these rights, Bayer will have to pay an upfront and option exercise fees of $20 million.
Seattle will also receive $500 million as a milestone payment, including royalties on the worldwide revenue generated by the products under this collaboration. It is also expected that the total royalty income will rise in the long run once the drug gains popularity.

Recs

1
Member Avatar TMFEBCapital (36.37) Submitted: 9/3/2013 8:57:09 AM : Outperform Start Price: $42.88 SGEN Score: -51.52

"A" list drug development collaborations offer milestone and royalty potential.

Recs

0
Member Avatar benyboy (< 20) Submitted: 9/3/2013 5:34:40 AM : Outperform Start Price: $42.88 SGEN Score: -51.52

cramer

Recs

1
Member Avatar zackf89 (< 20) Submitted: 8/9/2013 10:49:31 AM : Outperform Start Price: $41.94 SGEN Score: -46.71

ADCs, Platform play, Partnerships (Genentech, etc)

Recs

0
Member Avatar jamesdan567 (60.30) Submitted: 7/10/2013 1:37:00 PM : Outperform Start Price: $36.12 SGEN Score: -37.79

great management will achieve its goals over time

Recs

0
Member Avatar Treborn822 (88.67) Submitted: 6/21/2013 2:50:25 PM : Outperform Start Price: $30.24 SGEN Score: -25.34

Genetics

Recs

2
Member Avatar zzlangerhans (99.85) Submitted: 5/26/2013 3:49:12 AM : Outperform Start Price: $36.33 SGEN Score: -35.83

I recently terminated an old underperform pick on Seattle Genetics after being on the wrong side of a stock triple. I thought they were overvalued for their prospects at the time I made the pick, and perhaps they were, but pretty much everything has gone right for them since then. Now I find myself the owner of 150 shares bought for the #zzporte collaboration at 36.42. With the number of ongoing trials of Adcetris for different hematologic malignancies in progress, it's hard for me to make an assessment of their valuation and my last one was dead wrong anyway. In this case I'll just go with Portefeuille.

Recs

1
Member Avatar bychen (< 20) Submitted: 1/22/2013 11:11:45 AM : Outperform Start Price: $29.42 SGEN Score: -31.83

The technology is bearing fruit and could be applied to multiple cancers.

Recs

0
Member Avatar belmarque (< 20) Submitted: 6/18/2012 7:34:12 AM : Outperform Start Price: $25.36 SGEN Score: -29.86

Cancer killing drugs!

Recs

1
Member Avatar MDmomma (< 20) Submitted: 2/8/2012 3:40:53 PM : Outperform Start Price: $18.97 SGEN Score: +14.33

proprietary methods for linking antibody to cytotoxic drugs has potential to revolutionize chemotherapy

Results 1 - 20 of 77 : 1 2 3 4 Next »

Featured Broker Partners


Advertisement